Subsidies and existing MediSave schemes could possibly bring the out-of-pocket cost of Shingrix down to zero, says Health ...

India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

MediSave can be used to pay for the cost of the vaccine after subsidies from 2026. Read more at straitstimes.com.

Goldman Sachs downgraded Dynavax Technologies Corporation (NASDAQ:DVAX) reflecting updated views and recent competitive ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

The First in China! BLA Submitted for Luzhu Biotech's Recombinant Herpes Zoster Vaccine Expected to Be Launched in 2026 HONG KONG ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

Between Day 84 (one month after the second vaccine dose) and Day 421, anti-gE antibody geometric mean concentrations (GMC) declined for both amezosvatein (69.0%, n=49) and Shingrix (69.6% ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

SINGAPORE: The Ministry of Health (MOH) announced on Monday (Feb 10) that it will extend subsidies and MediSave usage for ...